CERo Therapeutics (CERO) announces it has concluded the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia, AML. The conclusion of the first cohort follows observation of cell expansion consistent with preclinical expectations, with no dose-limiting toxicities observed. The initial dose chosen for Cohort One was identical to the standard dose administered in CAR T therapy to B-cell lymphoma patients, where toxicity is commonly observed and treated in hospital. Additional dose infusions were administered to the second and third patients as the company continues forward with dose-finding investigations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- Cero Therapeutics ‘open’ to takeover bids, Axios reports
- CERo Therapeutics Updates Corporate Presentation on Innovations
- Cero doses third patient in starting dose cohort of Phase 1 CER-1236 trial
- Cero Therapeutics receives notice of allowance from USPTO for CER-1236
- Cero Therapeutics announces dose intensification in Phase 1 study of CER-1236